MAFB and hepatocellular carcinoma: By dividing the HCC patients into groups with higher or lower TFPI2 expression, it was seen that in the higher TFPI2 group, those with higher MAFB expression showed better DFS than those with lower MAFB expression (29.3 months vs. 12.9 months, p = 0.040) while, in the lower TFPI2 group, those with lower MAFF showed better DFS than those with higher MAFF expression (25.3 months vs. 16.5 months, p = 0.033) (see Figure 7A,C and Figure S8B).